Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Hospital Practice (1995)|August 2, 2018
Hospitalization costs of cystic fibrosis in the United States: a retrospective analysisPratyusha Vadagam, Khalid M KamalJournal of Managed Care & Specialty Pharmacy|December 23, 2020
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysisZsolt Hepp, Sonali N Shah, Karen Smoyer, et al.Journal of Managed Care & Specialty Pharmacy|September 25, 2018
Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic FibrosisPratyusha Vadagam, Khalid M Kamal, Jordan R Covvey, et al.Current Oncology (Toronto, Ont.)|April 25, 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature ReviewPratyusha Vadagam, Dexter Waters, Anil Bhagat, et al.Journal of Racial and Ethnic Health Disparities|May 19, 2023
Disparities in Lung Cancer: A Targeted Literature Review Examining Lung Cancer Screening, Diagnosis, Treatment, and Survival Outcomes in the United StatesLisa L Dwyer, Pratyusha Vadagam, Julie Vanderpoel, et al.Journal of Health Economics and Outcomes Research|May 22, 2026
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus ChemotherapyAlexander Spira, Pratyusha Vadagam, Iris Lin, et al.Cancer Treatment and Research Communications|May 23, 2025
Real-world treatment patterns of patients with EGFR exon 20 insertion-mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: A multi-database cohort studyAlexander Spira, Dexter Waters, Tao Ran, et al.Journal of Medical Economics|January 25, 2024
Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation typePratyusha Vadagam, Dexter Waters, Inyoung Lee, et al.Journal of Comparative Effectiveness Research|March 14, 2023
A value-based budget impact model for dronedarone compared with other rhythm control strategiesJennifer Ken-Opurum, Sesha Ss Srinivas, Pratyusha Vadagam, et al.Journal of Health Economics and Outcomes Research|September 2, 2025
Healthcare Resource Use, Healthcare Costs, and Unmet Needs Among Patients Treated for EGFR-Mutated Advanced or Metastatic Non-small Cell Lung CancerDavid Waterhouse, Iris Li, Laura Morrison, et al.Pageof 2